Eli Lilly’s Obesity Drug Zepbound Reduces Sleep Apnea in Late-Stage Studies
The injection lowered obstructive sleep apnea severity by up to nearly two-thirds in obese adults, with and without PAP therapy, in two phase 3 trials.
The injection lowered obstructive sleep apnea severity by up to nearly two-thirds in obese adults, with and without PAP therapy, in two phase 3 trials.
The researchers' method helped prevent harmful blood sugar spikes associated with COVID-19 and promoted lung recovery after COVID-19 and influenza pneumonia.
COPD patients who are extremely overweight (BMI > 40) do not benefit from the 'obesity paradox' of better mortality and morbidity.